NHL Study
Phase 1 study to evaluate the safety and preliminary efficacy of ATA3219 in subjects with relapsed/refractory B-cell non-Hodgkin’s lymphoma
REQUEST INFO
Clinical studies are necessary to investigate new therapies but they can’t move forward without patient participation which is essential. If you are interested in one of our clinical studies, please speak with your doctor or if you are a healthcare professional, please contact us for more information.
*EBV-associated diseases being studied include: EBV+ lymphoproliferative disease (LPD) in the setting of primary immunodeficiency (PID) (PID LPD); EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency (AID) (AID LPD); EBV+ posttransplant lymphoproliferative disorder involving the central nervous system (CNS PTLD); EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease; EBV+ sarcomas, including leiomyosarcoma (LMS).
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.
EBV=Epstein-Barr virus; EBV+=EBV positive; HLA=human leukocyte antigens; PTLD=post-transplant lymphoproliferative disease.